POTASSIUM CHLORIDE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- POTASSIUM CHLORIDE
- Generic name
- POTASSIUM CHLORIDE ORAL
- Manufacturer
- Saptalis Pharmaceuticals, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 483f338e-a164-4c1f-a34e-fef3312cb7ec
- SPL ID
- 5c17860b-20f1-2b92-e063-6294a90af2a4
- Version
- 6
- Effective date
- 2026-09-22
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:32:31
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 211648 | derived:openfda.application_number |
| application number | ANDA211648 | openfda.application_number | |
| brand name | POTASSIUM CHLORIDE | openfda.brand_name | |
| generic name | POTASSIUM CHLORIDE | openfda.generic_name | |
| generic name | POTASSIUM CHLORIDE ORAL | openfda.generic_name | |
| manufacturer name | Saptalis Pharmaceuticals, LLC | openfda.manufacturer_name | |
| ndc | package | 71656-021-51 | openfda.package_ndc |
| ndc | package | 71656-021-50 | openfda.package_ndc |
| ndc | package | 71656-021-01 | openfda.package_ndc |
| ndc | package | 71656-022-16 | openfda.package_ndc |
| ndc | package | 71656-022-01 | openfda.package_ndc |
| ndc | package | 71656-021-16 | openfda.package_ndc |
| ndc | package | 71656-021-02 | openfda.package_ndc |
| ndc | package | 71656-022-15 | openfda.package_ndc |
| ndc | package | 71656-022-50 | openfda.package_ndc |
| ndc | package | 71656-021-15 | openfda.package_ndc |
| ndc | package | 71656-021-30 | openfda.package_ndc |
| ndc | product | 71656-021 | openfda.product_ndc |
| ndc | product | 71656-022 | openfda.product_ndc |
| ndc11 | package | 71656002216 | derived:openfda.package_ndc |
| ndc11 | package | 71656002215 | derived:openfda.package_ndc |
| ndc11 | package | 71656002201 | derived:openfda.package_ndc |
| ndc11 | package | 71656002250 | derived:openfda.package_ndc |
| ndc11 | package | 71656002102 | derived:openfda.package_ndc |
| ndc11 | package | 71656002150 | derived:openfda.package_ndc |
| ndc11 | package | 71656002116 | derived:openfda.package_ndc |
| ndc11 | package | 71656002115 | derived:openfda.package_ndc |
| ndc11 | package | 71656002151 | derived:openfda.package_ndc |
| ndc11 | package | 71656002130 | derived:openfda.package_ndc |
| ndc11 | package | 71656002101 | derived:openfda.package_ndc |
| rxcui | 314182 | openfda.rxcui | |
| rxcui | 312515 | openfda.rxcui | |
| spl id | 5c17860b-20f1-2b92-e063-6294a90af2a4 | id | |
| spl set id | 483f338e-a164-4c1f-a34e-fef3312cb7ec | set_id | |
| unii | 660YQ98I10 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Dilute before use, take with meals ( 5.1 ) 5.1 Gastrointestinal Irritation May cause gastrointestinal irritation if administered undiluted. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration ( 2.1 )] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.